HomeAI · summaries
Storia in 5 fonti
FDA approves Lumvoa for thyroid eye disease
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics. The approval was supported by data from the phase 3 THRIVE and THRIVE-2 pivotal clinical trials, which investigated Lumvoa (veligrotug-vvze, 500 mg) for active and chronic thyroid eye disease (TED), respectively. In
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
- ·
endpoints.news
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion burden.
